ABSTRACT
BACKGROUND/OBJECTIVES: Phototherapy is a commonly used treatment for vitiligo that has demonstrated safety and efficacy. High-intensity targeted ultraviolet B (UVB) light (304-312 nm) delivered using a phototherapy device is a useful therapeutic option because it can induce repigmentation in a short time without global exposure to radiation, but information regarding this device in children is limited. METHODS: We performed a retrospective analysis of 95 patches of vitiligo in 27 children treated using a targeted phototherapy device. Phototherapy was administered twice a week. RESULTS: After the first 10 treatment sessions, 82 (86.3%) patches demonstrated some repigmentation and 36.8% achieved 50% or more repigmentation. After a mean of 20.4 treatment sessions, 86 patches (90%) demonstrated some repigmentation and 53.7% achieved 50% or more repigmentation. Responses varied depending on the anatomic location of the lesions. Better responses were usually observed on the face and trunk, whereas the extremities typically showed little response. Repigmentation was better in patients with active vitiligo than in those with stable vitiligo, with responses better with a disease duration of 1 year or less than in those with a duration of more than 1 year. There was no statistically significant difference in repigmentation between those with segmental and generalized vitiligo. The only short-term local side effect was mild erythema that required a decrease in dosage in six patients. CONCLUSION: Targeted high-intensity medium-band UVB phototherapy alone can produce clinical improvement in pediatric vitiligo and is well tolerated.
Subject(s)
Ultraviolet Therapy/methods , Vitiligo/radiotherapy , Adolescent , Child , Child, Preschool , Female , Humans , Male , Retrospective Studies , Treatment Outcome , Ultraviolet Therapy/adverse effectsABSTRACT
The prevalence of allergic diseases has increased over the past few decades. Atopic dermatitis (AD) is a common allergic disease, for which there is currently no known cure. Administration of probiotics in early life may be an effective method to prevent AD, but very little is known about its long-time preventive effect. In this research, a meta-analysis has been conducted to evaluate the long-term effect of early-life supplementation with probiotics on preventing AD. Meta-analysis was performed by the Review Manager version 5.2 software. Risk ratio and 95% confidence intervals were calculated by a fixed effect model. Six trials and a total of 1955 patients were included in this meta-analysis. The combined risk ratio of the meta-analysis comparing probiotics with placebo for investigating the long-term preventive effect of AD was 0.86 (95% CI 0.77-0.96), which demonstrates that probiotics is likely to produce long-term prevention of AD.